Results 231 to 240 of about 188,098 (288)

Low Molecular Weight Heparin Dosing in Relation to Postoperative Bleeding After Tracheotomy in Patients Infected With SARS-CoV-2-A Descriptive Study. [PDF]

Laryngoscope Investig Otolaryngol
Victorin D, Bergquist H, Hafsten L, Nihlén Å, Lindell E.   +4 more
europepmc   +1 more source

Giant cellulitis‐like Sweet's syndrome induced by gilteritinib

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Juan de Luque‐Fernández, Irene Rivera‐Ruiz, Irene Suárez‐Vergne, Inmaculada Sánchez‐Ramírez, Manuel Galán‐Gutiérrez, Antonio José Vélez García‐Nieto   +5 more
wiley   +1 more source

Real-world practices of low-molecular-weight heparin for venous thromboembolism prophylaxis in patients hospitalized with COVID-19: a multicenter prospective study from China. [PDF]

Thromb J
Xu F, Tao Y, Chen L, Zhang Y, Wang B, Han J, Deng C, Liu W, Fan G, Liang R, Chen Z, Chen Y, Zhen K, Zhang Y, Zhang Z, Zhang S, Wan J, Xie W, Yang P, Kang Y, Wang D, Wang C, Zhai Z.   +22 more
europepmc   +1 more source

CONKO-011/AIO-SUP-0115/ass.: Rivaroxaban Compared to Low Molecular Weight Heparin in Cancer Patients with Acute Venous Thromboembolism.

Oncol Res Treat
Sinn M, Lohneis A, Mohamed O, Roderburg C, Hellmann M, Südhoff T, Christoph DC, Krziwanie A, Heinz J, Semrau S, Schlenska-Lange A, Ettrich TJ, Trappe RU, Striefler JK, Pelzer U, Wernecke KD, Riess H.   +16 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Heparin and low-molecular-weight heparin

Thrombosis and Haemostasis, 2008
SummaryHeparin is one of the oldest biological medicines, and has an established place in the prevention and treatment of venous thrombosis. Low-molecular-weight heparins (LMWH) have been developed by several manufacturers and have advantages in terms of pharmacokinetics and convenience of administration.
Barbara Mulloy
exaly   +3 more sources

Low molecular weight heparins

Expert Opinion on Pharmacotherapy, 2000
Since its discovery, nearly 90 years, heparin has been used successfully for the treatment of thromboembolic processes. However, therapy with heparin has several important limitations. Most importantly, the poor predictability of its anticoagulant effects has led to the development of the low molecular weight heparins (LMWHs), which are derived from ...
O M, Aguilar, N S, Kleiman
openaire   +3 more sources

Low molecular weight heparins

Current Opinion in Cardiology, 1994
Low molecular weight heparins are derived from unfractionated heparin by chemical or enzymatic depolymerization; as a result, the mean molecular weight of unfractionated heparin is reduced by about one third and its biochemical and pharmacologic properties are improved.
B, Cosmi, J, Hirsh
openaire   +2 more sources

Heparins, Low-Molecular-Weight Heparins, and Pentasaccharides

Clinics in Geriatric Medicine, 2006
Elderly patients require special consideration when administered anticoagulants because of age-related alterations in renal function, protein binding, and increased bleeding risk. Unfractionated heparin can be used in most patients but difficulties with dosing and monitoring often lead to inadequate anticoagulation.
Danya L, Dinwoodey, Jack E, Ansell
openaire   +2 more sources